

Seth Baum

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7756715/seth-baum-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47
papers

1,939
citations

19
h-index

43
g-index

60
ext. papers

2,801
ext. citations

7.4
avg, IF

4.78
L-index

#	Paper	IF	Citations
47	Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a).. <i>Nature Medicine</i> , 2022 ,	50.5	23
46	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.. <i>European Heart Journal</i> , 2022 ,	9.5	8
45	Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. <i>American Journal of Preventive Cardiology</i> , 2021 , 8, 100278	1.9	2
44	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 264-275	18.1	28
43	Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States. <i>American Journal of Preventive Cardiology</i> , 2021 , 6, 100177	1.9	2
42	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. <i>Future Cardiology</i> , 2021 , 17, 155-174	1.3	7
41	Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2020 , 1, 100009	1.9	43
40	Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2020 , 382, 244-255	59.2	265
39	Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. <i>European Heart Journal</i> , 2020 , 41, 3936-3945	9.5	83
38	Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005404	5.8	29
37	Rounding the corner on residual risk: Implications of REDUCE-IT for omega-3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. <i>Clinical Cardiology</i> , 2019 , 42, 829	3.3	9
36	Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 901-909.e3	4.9	10
35	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1926-1942	15.1	19
34	Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 1780-1788	27.4	155
33	Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2019 , 394, 2012-2024	40	193
32	Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data. <i>The Lancet Digital Health</i> , 2019 , 1, e393-e402	14.4	24
31	Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified. <i>Therapeutics and Clinical Risk Management</i> , 2019 , 15, 1325-1332	2.9	2

30	PCSK9 inhibitor valuation: A science-based review of the two recent models. <i>Clinical Cardiology</i> , 2018 , 41, 544-550	3.3	6
29	Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). <i>American Journal of Cardiology</i> , 2018 , 121, 940-948	3	13
28	Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 662-680	15.1	215
27	The American Society for Preventive Cardiology. <i>Clinical Cardiology</i> , 2018 , 41, 709	3.3	1
26	Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 1234-1243.e5	4.9	25
25	A review of the evidence for alternative and complementary medical approaches in the prevention of atherosclerotic cardiovascular disease and diabetes. <i>Cardiovascular Endocrinology</i> , 2017 , 6, 39-43		1
24	Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2017 , 135, 2204-2206	16.7	28
23	CHARACTERISTICS OF PATIENTS APPROVED AND DENIED ACCESS TO PCSK9I THERAPY BY PAYERS. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2534	15.1	2
22	PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers. <i>Clinical Cardiology</i> , 2017 , 40, 243-254	3.3	52
21	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry. <i>Atherosclerosis</i> , 2017 , 267, 19-26	3.1	36
20	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017 , 19, 58	2.1	12
19	US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1223-9	4.9	41
18	Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice. <i>Postgraduate Medicine</i> , 2016 , 128 Suppl 1, 31-9	3.7	4
17	The American Society for Preventive Cardiology: Our 30-year legacy. <i>Clinical Cardiology</i> , 2016 , 39, 627-630	3.3	2
16	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 850-61	18.1	215
15	Accelerated atherosclerosis and elevated lipoprotein (a) after liver transplantation. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 434-7	4.9	2
14	Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. <i>Circulation: Cardiovascular Genetics</i> , 2016 , 9, 240-9		126
13	Statins and Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016 , 45, 87-100	5.5	10

12	Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia. <i>Reviews in Cardiovascular Medicine</i> , 2016 , 17, 16-27	3.9	2
11	Statins and diabetes. <i>Cardiology Clinics</i> , 2015 , 33, 233-43	2.5	12
10	Dissecting lipid and lipoprotein issues in women: an in utero-through-menopause journey. <i>Clinical Lipidology</i> , 2015 , 10, 431-448		
9	From the "Ivory Tower" to the trenches: A practical approach to the 2013 ACC/AHA Cholesterol and Risk Assessment Guidelines. <i>Journal of Clinical Lipidology</i> , 2014 , 8, 231-3	4.9	1
8	ANCHOR trial conclusions regarding the effects of pure eicosapentaenoic acid on low-density lipoprotein cholesterol. <i>American Journal of Cardiology</i> , 2013 , 111, 454-5	3	4
7	A Survey of Internists and Cardiologists: Are Discoveries in Fatty Acids Truly being translated into Clinical Practice?. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2013 , 88, 3-4	2.8	5
6	Pitfalls of population-based preventive medicine. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 310, 2201-2	27.4	2
5	EPA and DHA: distinct yet essential n-3 fatty acids. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 477; author reply 477-9	4.9	2
4	Fatty acids in cardiovascular health and disease: a comprehensive update. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 216-34	4.9	164
3	Fatty Acids and Their Derivatives in Cardiovascular Disease: Arachidonic, Eicosapentaenoic, and Docosahexaenoic Acids and Their Byproducts, the Eicosanoids and Docosanoids. <i>Current Cardiovascular Risk Reports</i> , 2012 , 6, 146-154	0.9	5
2	MR imaging in the definition of coronary artery anomalies. <i>Journal of Computer Assisted Tomography</i> , 1990 , 14, 171-4	2.2	15
1	Acute reversible diffuse conduction system disease due to Lyme disease. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1990 , 13, 1367-70	1.6	5